Treatment of tardive dyskinesia with galantamine: A randomized controlled crossover trial

Journal of Clinical Psychiatry

Volumn 68, Issue 3, 2007, Pages 410-415

  Caroff, Stanley N ^a,c   Walker, Patricia ^a   Campbell, E Cabrina ^a   Lorry, Alan ^a   Petro, Christopher ^a   Lynch, Kevin ^a   Gallop, Robert ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; PLACEBO;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; REBOUND; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 33947726216     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0309     Document Type: Article

References (55)

1. Miller DD, McEvoy JP, Davis S, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33-43
2. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd; 1995:1485-1495
3. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63 (suppl 4):12-19
4. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
5. Ross DE, Thomas M, Booth M, et al. Rate of tardive dyskinesia in hospitalized patients [letter]. Am J Psychiatry 2005;162:816
6. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609
7. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(suppl 4):5-9
8. Zhou FM, Wilson C, Dani JA. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003; 9:23-36
9. Tammenmaa IA, Sailas E, McGrath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1099-1107
10. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-Dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34: 713-738
11. Mahadik SP, Laev H, Korenovsky A, et al. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol Psychiatry 1988;24:199-217
12. Lohr JB, Caliguri MP, Manley MS, et al. Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytological methods. Psychopharmacol (Berl) 2000;148: 171-179
13. Grimm JW, Chapman MA, Zahm DS, et al. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 2001;39:51-57
14. Kelley JJ, Roberts RC. Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias. J Neural Transm 2004;111: 1075-1091
15. Terry AV Jr, Hill WD, Parikh V, et al. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 2003;28: 300-309
16. Parikh V, Terry AV, Khan MM, et al. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone and olanzapine. Psychopharmacology 2004;172:365-374
17. Tamminga CA, Smith RC, Ericksen SE, et al. Cholinergic influences in tardive dyskinesia. Am J Psychiatry 1977;134:769-774
18. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974;37: 941-947
19. Gerlach J, Reisby N, Randrap A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia 1974;34:21-35
20. Fann WE, Lake CR, Gerber CJ, et al. Cholinergic suppression of tardive dyskinesia. Psychopharmacologia 1974;37:101-107
21. Davis KL, Hollister LE, Barchas JD, et al. Choline in tardive dyskinesia and Huntington's disease. Life Sci 1976;19:1507-1516
22. Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berl) 1977;54:1-8
23. Lindeboom SF, Lakke JP. Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurol Scand 1978;58:134-138
24. Weiss KJ, Ciraulo DA, Shader RI. Physostigmine test in the rabbit syndrome and tardive dyskinesia. Am J Psychiatry 1980;137:627-628
25. Moore DC, Bowers MB Jr. Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes. Am J Psychiatry 1980;137: 1202-1205
26. Tarsy D, Leopold N, Sax DS. Physostigmine in choreiform movement disorders. Neurology 1974;24:28-33
27. Nasrallah HA, Pappas NJ, Crowe RR. Oculogyric dystonia in tardive dyskinesia. Am J Psychiatry 1980;137:850-851
28. Lieberman J, Pollack S, Lesser M, et al. Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 1988;8:254-260
29. Lieberman J, Lesser M, Johns C, et al. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988;8:57S-63S
30. Ingram NAW, Newgreen DB. The use of tacrine for tardive dyskinesia. Am J Psychiatry 1983;140:1629-1631
31. Caroff SN, Campbell EC, Havey J, et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001;62:772-775
32. Schopick D. Donepezil and tardive dyskinesia [letter]. J Am Acad Child Adolesc Psychiatry 2005;44:112
33. Bergman J, Dwolatzky T, Brettholz I, et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry 2005;66:107-110
34. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001;49:289-299
35. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487
36. Pharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
37. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667
38. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217
39. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
40. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res 1975;12:189-198
41. Barnes TRE. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-676
42. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
43. Laird NM, Ware JH. Random effect model for longitudinal data. Biometrics 1982;38:963-974
44. Littrell RC, Milliken GA, Stroup WW, et al. SAS system for mixed models. Cary, NC: SAS Institute Inc; 1996
45. Altavista MC, Bentivoglio AR, Crociani P, et al. Age-dependent loss of cholinergic neurons in basal ganglia of rats. Brain Res 1988;455: 177-181
46. Holt DJ, Bachus SE, Hyde TM, et al. Reduced density of cholinergic neurons in the ventral striatum in schizophrenia: an in-situ hybridization study. Biol Psychiatry 2005;58:408-416
47. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003;160:118-127
48. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 2004;174:45-53
49. Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 2005;28:139-141
50. Stryjer R, Strous R, Bar F, et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double-blind cross-over study. Hum Psychopharmacol 2004;19:343-346
51. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology 2005;181:358-363
52. Dengiz AN, Kershaw P. Clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. CNS Spectr 2004;9:377-392
53. Aarsland D, Hutchinson M, Lansen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941
54. Edwards KR, Hershey L, Wray L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord 2004;17(suppl 1):40-48
55. Caroff SN, Martine R, Kleiner-Fisman G, et al. Treatment of levodopa-induced dyskinesias with donepezil. Parkinsonism Relat Disord 2006;12: 261-263